AlphAIAlphAI — Financial news for AI agents
investing.comOCT 302 min read$THC

Guggenheim lowers Tenet Healthcare stock price target on 2027 outlook

Guggenheim reduced its price target for Tenet Healthcare (NYSE:THC) to $306 from $307, maintaining a Buy rating. The firm cited a modestly revised 2027 EBITDA outlook. Tenet's Q3 2026 earnings beat estimates, with adjusted EPS of $6.64 vs. $4.67 and revenue of $5.63B vs. $5.49B. The stock trades at $270.57, with a P/E ratio of 10.36 and a free cash flow yield of 15%.

Original reporting
investing.com
Published Oct 30, 2026, 12:08 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 30, 2026, 12:18 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefEarnings
Primary signal
$THC
Bearish
high confidence
Mentioned
$THC
Relevance
8/10
AlphAI data visualization · based on investing.com
Decision brief

The 30-second read

$THCBearishMed
01

Why it matters

Analyst target reduction may outweigh earnings beat, creating short-term downside risk.

02

Market read

The mixed news of an earnings beat and a lowered price target creates a nuanced trading signal for THC.

03

What to watch

Potential upside from upcoming Medicaid policy changes and USPI's insulated position may not be fully priced in.

Relevance 8/10Novelty 7/10Timing: pre-market today

Background

Tenet Healthcare reported Q3 2026 earnings that beat consensus, while Guggenheim adjusted its 2027 outlook and lowered its price target.

Company-level read

Ticker impact

$THCBearishHigh confidence
Context

Guggenheim lowered its price target on Tenet Healthcare to $306 and reported the company's Q3 2026 earnings beat expectations.

Expected impact

likely pressure as the market prices in the lower 2027 outlook and target reduction

Evidence & confidence

Analyst target reduction signals concerns over 2027 EBITDA despite strong Q3 results, which may outweigh the earnings beat in short-term price action.

Market effects

Sector

The target cut may prompt a reassessment of healthcare services stocks with similar exposure to USPI contracts.

Regional

U.S. healthcare sector could see modest pullback in early trading.

Global

Limited to U.S. markets; no immediate global ripple.

Counterpoint

What could challenge this read

The earnings beat and strong free cash flow could support a price rally despite the modest target cut.

Key entities

  • company
    Tenet Healthcare

    U.S. healthcare services provider (ticker THC).

  • research_firm
    Guggenheim

    Equity research firm that issued the price target change.

Read at source← All news

Related articles

OCT 31
$THCMed

Tenet Healthcare Q3 Earnings Call Highlights

Tenet Healthcare (THC) reported Q3 earnings, with hospital segment showing 3.2% growth in admissions and 11% adjusted EBITDA increase. Revenue per admission rose 0.2% YoY. Exchange admissions and revenues declined 18%. Conifer transition activities contributed $147M, with $450M expected in 2026. Tenet generated $1.1B in adjusted free cash flow and repurchased 970K shares.

finance.yahoo.com6 min
OCT 30
$THCMed

High-acuity strategy helped Tenet weather surgery, uninsured headwinds in Q3

Tenet Healthcare raised its 2026 earnings guidance after its focus on high-acuity surgeries helped offset Q3 declines in procedure volumes. CEO Saum Sutaria cited the strategy's role in mitigating financial headwinds, including rising uninsured rates. Tenet expects full-year net income of $2.97B-$3.08B on revenues of $22.1B-$22.5B. Analysts noted Tenet's results were solid despite a challenging hospital sector.

finance.yahoo.com6 min
OCT 29
$THCMedAI 8/10

Tenet Healthcare Corp (THC) Q3 2026 Earnings Call Highlights: Strong EPS Growth

Tenet Healthcare Corp (THC) reported Q3 2026 adjusted diluted EPS of $6.64, up 80%, driven by strong core business growth. USPI adjusted EBITDA rose 9% to $537 million, while hospital segment admissions grew 3.2%. Full-year 2026 adjusted EBITDA guidance was raised by $195 million. Challenges include exchange admissions decline and Conifer transition impacts. Management remains optimistic about 2027 earnings growth.

finance.yahoo.com6 min
OCT 29
$THCHighAI 9/10

Tenet (THC) Q3 2026 Earnings Call Transcript

Tenet Healthcare (THC) reported Q3 2026 revenue of $5.631B (+6.5% YoY) and adjusted EPS of $6.64 (+79.5% YoY). Adjusted EBITDA was $1.355B, with growth in ambulatory and hospital segments. The company raised FY2026 EBITDA guidance to $5.05B-$5.20B. Risks include an 18% decline in exchange admissions and Medicaid work requirements. Tenet issued $2B in senior unsecured notes and repurchased $1.615B in shares YTD.

fool.com3 min
OCT 29
$THCMedAI 9/10

Tenet Healthcare Boosts FY26 Earnings Outlook - Update

Tenet Healthcare (THC) raised its FY26 earnings and adjusted earnings guidance, while narrowing its revenue outlook. The company now expects earnings of $35.82-$37.08 per share, adjusted earnings of $22.05-$23.01 per share, and revenue of $22.05-$22.45 billion. Shares were unchanged at $268.50 in pre-market trading.

rttnews.com2 min